Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Published in NEJM an amazing story of ‘genomics is THE diagnosis for sarcoma in an infant’ ‘Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion’ Precision Medicine for the win.”
Quoting an older post:
“Hot off the press- Pre-proof version. Pleased to share our Editorial in ESMO flagship journal Annals of Oncology ‘Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward’ Dr. Razelle Kurzrock and I opine that ‘Consensus must accelerate our field, not delay it. For many sarcomas, genomics isn’t ancillary, it IS the DIAGNOSIS’.
Huge congrats to Annals of Oncology for its exceptional leadership in the field standing as one of oncology’s most highly cited journals (IF 80+)”
Title: Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion
Authors: Shampavi Sri Haran, Lucy Cain, Artur Darmanian, Michael Krivanek, Dale Wright, Wayne Nicholls, Martin Lowe, Luciano Dalla-Pozza, Bruce Goodwin, Jane McEniery, Kevin Hardin, Ashleigh Sullivan, Natacha Omer
Other articles featuring Vivek Subbiah on OncoDaily.